Decision: Favourable

Decisions Table

Study Title:

The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease

  • NREC Code:

    22-NREC-CT-186

  • Decision:

    Favourable

  • Meeting Date:

    11/01/2023

  • Study Type:

    CT Application

  • Principal Investigator:

    Dr Maria Byrne

  • PI Institution:

    Mater Misericordiae University Hospital

  • Sponsor:

    Novo Nordisk Ltd

Scroll to Top